KBC Group NV Acquires 87,947 Shares of LivaNova PLC $LIVN

KBC Group NV grew its holdings in LivaNova PLC (NASDAQ:LIVN) by 202.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 131,434 shares of the company’s stock after acquiring an additional 87,947 shares during the period. KBC Group NV’s holdings in LivaNova were worth $8,354,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SG Americas Securities LLC increased its stake in LivaNova by 83.9% in the fourth quarter. SG Americas Securities LLC now owns 24,257 shares of the company’s stock valued at $1,493,000 after acquiring an additional 11,066 shares during the period. Exchange Traded Concepts LLC bought a new position in LivaNova during the fourth quarter worth about $970,000. Tudor Investment Corp ET AL bought a new position in LivaNova during the third quarter worth about $1,746,000. Peregrine Capital Management LLC acquired a new stake in LivaNova during the fourth quarter valued at approximately $3,830,000. Finally, F m Investments LLC boosted its holdings in LivaNova by 46.9% during the fourth quarter. F m Investments LLC now owns 114,458 shares of the company’s stock valued at $7,043,000 after purchasing an additional 36,543 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on LIVN shares. Mizuho increased their target price on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Robert W. Baird decreased their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Freedom Capital upgraded LivaNova to a “hold” rating in a research report on Tuesday, June 30th. KeyCorp increased their price objective on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, June 22nd. Finally, Barclays lifted their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $81.38.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director owned 7,228 shares of the company’s stock, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.35% of the stock is currently owned by insiders.

LivaNova Stock Performance

Shares of LivaNova stock opened at $78.27 on Thursday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The firm has a market cap of $4.30 billion, a P/E ratio of 40.14 and a beta of 0.86. The firm has a 50 day simple moving average of $78.00 and a 200 day simple moving average of $69.36. LivaNova PLC has a fifty-two week low of $41.01 and a fifty-two week high of $85.27.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Sell-side analysts predict that LivaNova PLC will post 3.73 earnings per share for the current fiscal year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.